Nordion is realigning to create two business units: Targeted Therapies and Specialty Isotopes. The Specialty Isotopes segment will include Sterilization Technologies and Medical Isotopes.
"The new organizational model is intended to allow for quicker decision-making and provide the Nordion team with improved agility, clearer focus, and direct leadership accountability to better serve our customers and build shareholder value," noted Nordion CEO Steven West in a prepared statement.
Scott McIntosh, who formerly served as senior vice president of operations, will head Specialty Isotopes as chief operating officer (COO) and will serve as general manager of Sterilization Technologies.
Tom Burnett will serve as Medical Isotopes' general manager. He was formerly vice president of global sales at Nordion.
West will act as interim COO of Targeted Therapies while the company begins an external search for a permanent head.
